Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

PR Newswire October 29, 2019

Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

PR Newswire October 17, 2019

Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX?102) for the Treatment of Fabry Disease

PR Newswire September 24, 2019

Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

GlobeNewswire August 30, 2019

Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

GlobeNewswire August 22, 2019

Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

GlobeNewswire August 13, 2019

Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update

GlobeNewswire August 8, 2019

Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019

GlobeNewswire July 29, 2019

Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

GlobeNewswire July 29, 2019

Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease

GlobeNewswire June 17, 2019

Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

GlobeNewswire June 6, 2019

Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update

GlobeNewswire May 6, 2019

Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019

GlobeNewswire April 29, 2019

Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease

GlobeNewswire December 17, 2018

Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update

GlobeNewswire November 7, 2018

Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

GlobeNewswire October 29, 2018

New Research: Key Drivers of Growth for Cenovus Energy, Protalix BioTherapeutics, Rayonier Advanced Materials, B2Gold, Match Group, and Qudian Inc. Sponsored ADR — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire October 17, 2018

Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

GlobeNewswire October 5, 2018

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Benzinga.com  September 30, 2018

Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease

GlobeNewswire September 21, 2018